Vascular Biogenics Ltd (VBLT)

[davidal66]

The most interesting part of today's press release below was the tail of survivors(40%)after many years, but also interesting that 8/17 - 44 % of patients had reduction in tumor size after the first dose in the high dose cohort as opposed to 1/11 - 9% of patients in the low-dose cohort. This sounds like more than placebo to me.

The primary endpoint of the trial, defined as 6-month progression-free-survival (PFS-6) of 25%, was met with a dose response. Forty-seven percent (47%; 8/17) of patients in the therapeutic-dose cohort reached PFS-6, versus 25% (4/12) in the sub-therapeutic cohort, both groups meeting the primary endpoint. Reduction in tumor measurement after the first dose was seen in 44% (7/16) of patients in the therapeutic-dose cohort, compared to 9% (1/11) in the sub-therapeutic-dose cohort. An overall survival benefit was seen with a tail of more than 40% at 3.7 years for the therapeutic-dose cohort (mOS 684 days).